Research continues into new ways of preventing and curing A-Fib, boosted by ever-increasing new technologies. Catheter ablation has become a mainstream treatment for the disease due to greater    technological accuracy. It is widely recognised that the impact of Atrial Fibrillation (A-Fib) is not only responsible for significant cardiovascular and cerebrovascular morbidity and mortality, but is also placing severe strain on healthcare resources.
Eliminating Latent TB
Latent TB in healthcare workers is a major threat to patients. Traditional tests have too often been unable to detect the condition reliably. A new blood test looks set to change this, which is good news for patients – and healthcare workers.
Cowen analysts – Rotation in health-care stocks
Bracing for a rocky 2008, investors in health-care stocks are increasingly moving their cash out of “one-hit” wonder drug developers and into companies with broader-based product portfolios, according to analysts at Cowen and Co.
Cook Medical Announces FDA 510(k) Clearance of Evolution® Controlled Release Esophageal Stent System
Cook Medical announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of the Evolution® Controlled Release Esophageal Stent System.
Gambro BCT, Inc., medical device manfacturer soon to become CaridianBCT, Inc.,
Gambro BCT, Inc., the largest medical device manufacturer headquartered in Colorado, with worldwide revenues approaching $500M and 2300 employees, announced it will change its legal name to CaridianBCT, Inc. on July 14, 2008. The Lakewood, CO-based company was a subsidiary of Gambro AB, a previously publicly traded, multinational healthcare company based in Sweden. It currently operates as an independent U.S. corporation under a private ownership structure.